CONMED Corporation Company Profile (NASDAQ:CNMD)

About CONMED Corporation (NASDAQ:CNMD)

CONMED Corporation logoCONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. The Company's product lines consist of orthopedic surgery, general surgery and surgical visualization. As of December 31, 2016, the Company's products are distributed domestically directly to over 6,000 hospitals, surgery centers and other healthcare institutions, as well as through medical specialty distributors. The Company's orthopedic surgery product lines include sports medicine, powered surgical instruments, and sports biologics and tissue. These products are marketed under a range of brands, including Hall, CONMED Linvatec, Concept and Shutt.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:CNMD
  • CUSIP: 20741010
  • Web:
  • Market Cap: $1.46 billion
  • Outstanding Shares: 27,924,000
Average Prices:
  • 50 Day Moving Avg: $51.31
  • 200 Day Moving Avg: $49.99
  • 52 Week Range: $37.60 - $54.47
  • Trailing P/E Ratio: 93.72
  • Foreward P/E Ratio: 25.81
  • P/E Growth: 5.23
Sales & Book Value:
  • Annual Revenue: $772.61 million
  • Price / Sales: 1.89
  • Book Value: $20.86 per share
  • Price / Book: 2.51
  • Annual Dividend: $0.80
  • Dividend Yield: 1.6%
  • EBITDA: $123.91 million
  • Net Margins: 2.02%
  • Return on Equity: 8.38%
  • Return on Assets: 3.66%
  • Debt-to-Equity Ratio: 0.83%
  • Current Ratio: 2.62%
  • Quick Ratio: 1.57%
  • Average Volume: 107,597 shs.
  • Beta: 0.68
  • Short Ratio: 7.44

Frequently Asked Questions for CONMED Corporation (NASDAQ:CNMD)

What is CONMED Corporation's stock symbol?

CONMED Corporation trades on the NASDAQ under the ticker symbol "CNMD."

How often does CONMED Corporation pay dividends? What is the dividend yield for CONMED Corporation?

CONMED Corporation announced a quarterly dividend on Tuesday, August 29th. Shareholders of record on Friday, September 15th will be paid a dividend of $0.20 per share on Thursday, October 5th. This represents a $0.80 dividend on an annualized basis and a yield of 1.53%. The ex-dividend date is Thursday, September 14th. View CONMED Corporation's Dividend History.

How were CONMED Corporation's earnings last quarter?

CONMED Corporation (NASDAQ:CNMD) announced its quarterly earnings data on Wednesday, July, 26th. The company reported $0.41 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.41. The firm had revenue of $197.20 million for the quarter, compared to analysts' expectations of $194.50 million. CONMED Corporation had a return on equity of 8.38% and a net margin of 2.02%. The firm's revenue was up 2.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.47 earnings per share. View CONMED Corporation's Earnings History.

When will CONMED Corporation make its next earnings announcement?

CONMED Corporation is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for CONMED Corporation.

What guidance has CONMED Corporation issued on next quarter's earnings?

CONMED Corporation issued an update on its FY17 earnings guidance on Wednesday, July, 26th. The company provided earnings per share guidance of $1.85-1.95 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.86.

Where is CONMED Corporation's stock going? Where will CONMED Corporation's stock price be in 2017?

4 brokerages have issued 1-year price objectives for CONMED Corporation's shares. Their predictions range from $43.00 to $57.00. On average, they expect CONMED Corporation's share price to reach $49.33 in the next year. View Analyst Ratings for CONMED Corporation.

What are analysts saying about CONMED Corporation stock?

Here are some recent quotes from research analysts about CONMED Corporation stock:

  • 1. According to Zacks Investment Research, "Over the past three months CONMED Corporation has outperformed the broader industry trends in terms of price performance. CONMED offers a broad line of surgical products. The company’s product pipeline consists of several new devices including new sports medicine products,  endomechanical offerings, a new electrosurgical council and the latest 2D Arthroscopy video system. With increased product offerings, the company can accelerate its top line. The company has recently registered strong second-quarter results wherein adjusted earnings beat the Zacks Consensus Estimate, while revenues also did the same. On the flipside, foreign exchange movements have been unfavorably impacting the company’s results of late. Additionally, the company operates in a highly competitive environment which is likely to mar the top-line growth. Furthermore, a falling estimate revision trend for the current year indicates looming concerns ahead of the stock." (7/28/2017)
  • 2. Needham & Company LLC analysts commented, "CNMD’s 1Q17 revenue and EPS beat consensus and management maintained its 2017 guidance. Importantly, CNMD’s revenue growth (arguably the most important metric at this point) improved to 3.7% CC in 1Q17 from (1.5%) CC in 4Q16. This is the highest organic growth CNMD has seen in the past six years. While comps get a bit more difficult in the next few quarters, new products (particularly in the Orthopedic Surgery business) should begin to meaningfully contribute to growth by 2H17." (4/27/2017)
  • 3. Leerink Swann analysts commented, "We remain cautious on the company’s ability to manage through what we believe could be meaningful top-line headwinds in F2H17 and FY2018 in order to return to and sustain a solid mid- single-digit growth trajectory after just 3% growth in F2Q17, including: (1) A competitive CRM (cardiac rhythm management) product cycle, (2) Current and upcoming competitive launches in DES (drug eluting stents), (3) Potential modest share loss in U.S. TAVR (transcatheter aortic valve replacement) with a competitor recently receiving an expanded indication that is likely ~12-18 months ahead of MDT only partially offset by MDT’s recent large valve size launch; and (4) Continued share loss in Neuromodulation, particularly in SCS (spinal cord stimulation), DBS (deep brain stimulation), and implantable drug infusion pumps." (11/23/2016)

Who are some of CONMED Corporation's key competitors?

Who are CONMED Corporation's key executives?

CONMED Corporation's management team includes the folowing people:

  • Mark E. Tryniski, Independent Chairman of the Board
  • Curt R. Hartman, President, Chief Executive Officer, Director
  • Luke A. Pomilio, Chief Financial Officer, Executive Vice President - Finance
  • Patrick J. Beyer, President of CONMED International
  • Daniel S. Jonas, Executive Vice President - Legal Affairs, General Counsel
  • Heather L. Cohen, Executive Vice President - Human Resources, Secretary
  • Wilfredo Ruiz-Caban, Executive Vice President - Quality Assurance, Regulatory Affairs and Operations
  • Peter K. Shagory, Executive Vice President - Strategy and Corporate Development
  • Nathan Folkert, Vice President, General Manager - U.S. Orthopedics Business
  • John E. Kennedy, Vice President and General Manager - U.S. Endoscopic Technologies

How do I buy CONMED Corporation stock?

Shares of CONMED Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CONMED Corporation's stock price today?

One share of CONMED Corporation stock can currently be purchased for approximately $52.39.

MarketBeat Community Rating for CONMED Corporation (NASDAQ CNMD)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  191 (Vote Outperform)
Underperform Votes:  155 (Vote Underperform)
Total Votes:  346
MarketBeat's community ratings are surveys of what our community members think about CONMED Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for CONMED Corporation (NASDAQ:CNMD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $49.33 (5.83% downside)
Consensus Price Target History for CONMED Corporation (NASDAQ:CNMD)
Price Target History for CONMED Corporation (NASDAQ:CNMD)
Analysts' Ratings History for CONMED Corporation (NASDAQ:CNMD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/1/2017Needham & Company LLCReiterated RatingBuy$57.00LowView Rating Details
8/25/2017KeyCorpReiterated RatingHoldLowView Rating Details
4/27/2017Ladenburg Thalmann Financial ServicesDowngradeBuy -> Neutral$50.00 -> $48.00HighView Rating Details
11/23/2016Leerink SwannReiterated RatingHold -> NeutralN/AView Rating Details
11/17/2015Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
10/22/2015Northland SecuritiesLower Price TargetMarket Perform$58.00 -> $44.00N/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for CONMED Corporation (NASDAQ:CNMD)
Earnings by Quarter for CONMED Corporation (NASDAQ:CNMD)
Earnings History by Quarter for CONMED Corporation (NASDAQ CNMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017$0.42N/AView Earnings Details
7/26/2017Q2 2017$0.41$0.41$194.50 million$197.20 millionViewN/AView Earnings Details
4/26/2017Q1 2017$0.35$0.38$181.47 million$186.57 millionViewN/AView Earnings Details
2/1/2017Q416$0.56$0.54$204.04 million$204.10 millionViewListenView Earnings Details
10/27/2016Q316$0.41$0.41$180.13 million$184.79 millionViewListenView Earnings Details
7/27/2016Q216$0.46$0.47$191.48 million$193.40 millionViewListenView Earnings Details
4/27/2016Q116$0.41$0.42$180.15 million$181.20 millionViewListenView Earnings Details
1/27/2016Q415$0.51$0.52$191.03 million$191.00 millionViewListenView Earnings Details
10/21/2015Q315$0.44$0.38$173.96 million$169.20 millionViewListenView Earnings Details
7/21/2015Q215$0.44$0.36$182.40 million$181.00 millionViewListenView Earnings Details
4/22/2015Q115$0.41$0.42$176.16 million$177.90 millionViewListenView Earnings Details
1/27/2015Q414$0.54$0.53$196.00 million$195.00 millionViewListenView Earnings Details
10/23/2014Q314$0.39$0.44$173.30 million$175.00 millionViewListenView Earnings Details
7/23/2014Q214$0.47$0.47$190.62 million$188.20 millionViewListenView Earnings Details
4/24/2014Q1$0.47$0.49$191.95 million$181.90 millionViewListenView Earnings Details
2/13/2014Q413$0.49$0.53$197.24 million$203.40 millionViewListenView Earnings Details
10/24/2013Q313$0.40$0.40$186.20 million$179.30 millionViewListenView Earnings Details
7/24/2013Q2 2013$0.44$0.43$193.55 million$193.00 millionViewListenView Earnings Details
4/25/2013Q1 2013$0.45$0.45$196.79 million$187.00 millionViewListenView Earnings Details
2/14/2013Q4 2012$0.50$0.52$200.12 million$201.20 millionViewListenView Earnings Details
10/25/2012$0.40$0.43ViewN/AView Earnings Details
7/26/2012$0.45$0.43ViewN/AView Earnings Details
4/26/2012$0.44$0.43ViewN/AView Earnings Details
2/15/2012$0.39$0.46ViewN/AView Earnings Details
10/27/2011$0.31$0.33ViewN/AView Earnings Details
7/28/2011$0.35$0.35ViewN/AView Earnings Details
4/28/2011$0.31$0.37ViewN/AView Earnings Details
2/3/2011$0.36$0.36ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for CONMED Corporation (NASDAQ:CNMD)
2017 EPS Consensus Estimate: $1.87
2018 EPS Consensus Estimate: $2.14
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.30$0.37$0.34
Q2 20172$0.41$0.44$0.43
Q3 20172$0.39$0.40$0.40
Q4 20172$0.70$0.72$0.71
Q1 20181$0.46$0.46$0.46
Q2 20181$0.56$0.56$0.56
Q3 20181$0.46$0.46$0.46
Q4 20181$0.66$0.66$0.66
(Data provided by Zacks Investment Research)


Current Dividend Information for CONMED Corporation (NASDAQ:CNMD)
Most Recent Dividend:10/5/2017
Annual Dividend:$0.80
Dividend Yield:1.53%
Payout Ratio:142.86% (Trailing 12 Months of Earnings)
42.78% (Based on This Year's Estimates)
39.41% (Based on Next Year's Estimates)
Dividend Payments by Quarter for CONMED Corporation (NASDAQ:CNMD)

Dividend History by Quarter for CONMED Corporation (NASDAQ CNMD)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for CONMED Corporation (NASDAQ:CNMD)
Insider Ownership Percentage: 2.62%
Institutional Ownership Percentage: 98.32%
Insider Trades by Quarter for CONMED Corporation (NASDAQ:CNMD)
Institutional Ownership by Quarter for CONMED Corporation (NASDAQ:CNMD)
Insider Trades by Quarter for CONMED Corporation (NASDAQ:CNMD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/3/2017Charles FarkasDirectorBuy148$53.96$7,986.08View SEC Filing  
8/14/2017Jo Ann GoldenDirectorSell3,000$50.00$150,000.00View SEC Filing  
7/5/2017Charles FarkasDirectorBuy157$50.78$7,972.46View SEC Filing  
6/13/2017Dirk KuyperDirectorSell1,000$52.24$52,240.00View SEC Filing  
5/15/2017Daniel JonasEVPSell3,000$51.22$153,660.00View SEC Filing  
4/3/2017Charles FarkasDirectorBuy180$44.41$7,993.80View SEC Filing  
3/13/2017Heather L CohenEVPBuy440$40.00$17,600.00View SEC Filing  
3/10/2017Curt R HartmanCEOBuy8,030$40.11$322,083.30View SEC Filing  
3/6/2017Mark E TryniskiDirectorBuy5,000$41.15$205,750.00View SEC Filing  
1/3/2017Charles FarkasDirectorBuy305$44.65$13,618.25View SEC Filing  
11/8/2016Daniel JonasEVPSell1,500$41.78$62,670.00View SEC Filing  
11/7/2016Daniel JonasEVPSell2,555$40.40$103,222.00View SEC Filing  
10/3/2016Charles FarkasDirectorBuy336$40.04$13,453.44View SEC Filing  
7/1/2016Charles FarkasDirectorBuy282$47.87$13,499.34View SEC Filing  
6/3/2016Luke A PomilioCFOSell4,400$41.56$182,864.00View SEC Filing  
4/1/2016Charles FarkasDirectorBuy338$42.04$14,209.52View SEC Filing  
3/4/2016Mark D SnyderEVPSell2,940$41.32$121,480.80View SEC Filing  
3/2/2016John L WorkmanDirectorBuy2,500$39.85$99,625.00View SEC Filing  
2/19/2016Jerome J LandeDirectorSell1,630,800$38.28$62,427,024.00View SEC Filing  
1/4/2016Charles FarkasDirectorBuy332$42.18$14,003.76View SEC Filing  
12/11/2015David M BronsonDirectorBuy1,500$41.01$61,515.00View SEC Filing  
6/12/2015Jo Ann GoldenDirectorSell1,000$56.03$56,030.00View SEC Filing  
5/29/2015Stephen MandiaDirectorSell14,000$55.62$778,680.00View SEC Filing  
5/6/2015Pat BeyerInsiderBuy5,000$53.36$266,800.00View SEC Filing  
4/30/2015Stephen MandiaDirectorSell3,899$49.97$194,833.03View SEC Filing  
12/12/2014Stephen MandiaDirectorSell4,500$43.23$194,535.00View SEC Filing  
12/1/2014Dirk KuyperDirectorSell1,000$42.85$42,850.00View SEC Filing  
11/19/2014Joseph G DarlingEVPSell4,270$42.00$179,340.00View SEC Filing  
10/29/2014Robert D Shallish JrCFOSell10,410$41.67$433,784.70View SEC Filing  
9/4/2014William AbrahamEVPSell16,062$39.91$641,034.42View SEC Filing  
8/26/2014William AbrahamEVPSell7,423$38.36$284,746.28View SEC Filing  
8/21/2014William AbrahamEVPSell15,986$37.71$602,832.06View SEC Filing  
8/19/2014William AbrahamEVPSell5,312$37.75$200,528.00View SEC Filing  
7/31/2014Curt R HartmanCEOBuy10,000$39.25$392,500.00View SEC Filing  
7/30/2014Bruce DanielsDirectorSell1,600$39.31$62,896.00View SEC Filing  
7/30/2014Joseph J CorasantiCEOSell109,035$39.25$4,279,623.75View SEC Filing  
10/29/2013Joseph J CorasantiCEOSell80,148$36.47$2,922,997.56View SEC Filing  
10/28/2013Bruce DanielsDirectorSell4,500$36.43$163,935.00View SEC Filing  
9/13/2013Joseph CorasantiCEOSell44,852$33.04$1,481,910.08View SEC Filing  
9/11/2013William AbrahamSVPSell7,423$33.48$248,522.04View SEC Filing  
8/15/2013Dirk KuyperDirectorBuy1,000$31.63$31,630.00View SEC Filing  
6/7/2013Daniel JonasVPSell2,000$32.42$64,840.00View SEC Filing  
6/4/2013Heather L CohenVPSell1,200$32.59$39,108.00View SEC Filing  
5/31/2013Luke A PomilioVPSell2,556$33.19$84,833.64View SEC Filing  
5/29/2013Heather L CohenVPSell4,514$34.31$154,875.34View SEC Filing  
5/28/2013Robert D Shallish JrCFOSell10,000$34.35$343,500.00View SEC Filing  
2/15/2013Stuart J SchwartzDirectorSell1,000$30.32$30,320.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for CONMED Corporation (NASDAQ:CNMD)
Latest Headlines for CONMED Corporation (NASDAQ:CNMD)
DateHeadline logoContrasting CONMED Corporation (CNMD) & Its Competitors - October 14 at 4:28 PM logoETFs with exposure to CONMED Corp. : October 10, 2017 - October 10 at 6:33 PM logoCONMED Corporation to Announce Third Quarter 2017 Financial Results on November 2, 2017 - October 10 at 6:33 PM logo$187.21 Million in Sales Expected for CONMED Corporation (CNMD) This Quarter - October 6 at 5:56 AM logoCONMED Corp. : CNMD-US: Dividend Analysis : September 15th, 2017 (record date) : By the numbers : October 5, 2017 - October 5 at 11:09 AM logoAnalyzing NeuroMetrix (NURO) and CONMED Corporation (CNMD) - October 4 at 10:38 AM logoHead to Head Review: Orthofix International N.V. (OFIX) versus CONMED Corporation (CNMD) - October 1 at 2:20 PM logoCONMED Corporation (CNMD) Given Average Recommendation of "Hold" by Brokerages - September 24 at 6:48 AM logoHead to Head Contrast: CONMED Corporation (CNMD) vs. The Competition - September 15 at 8:46 PM logoCONMED Corp. – Value Analysis (NASDAQ:CNMD) : September 14, 2017 - September 13 at 11:37 PM logoCONMED Corp. breached its 50 day moving average in a Bullish Manner : CNMD-US : September 12, 2017 - September 12 at 6:02 PM logoCONMED Corporation's (CNMD) "Buy" Rating Reiterated at Needham & Company LLC - September 4 at 10:38 PM logoCritical Analysis: CONMED Corporation (CNMD) & K2M Group Holdings (KTWO) - August 31 at 6:12 PM logo Brokerages Anticipate CONMED Corporation (CNMD) Will Post Quarterly Sales of $187.21 Million - August 30 at 10:00 AM logoCONMED Corporation (CNMD) Receives Consensus Recommendation of "Hold" from Analysts - August 30 at 6:46 AM logoCritical Review: Meridian Bioscience (VIVO) versus CONMED Corporation (CNMD) - August 30 at 6:28 AM logoWhy Is CONMED (CNMD) Down 2.9% Since the Last Earnings Report? - August 29 at 5:45 PM logoCONMED Corporation (CNMD) Announces Quarterly Dividend of $0.20 - August 29 at 4:48 PM logoCONMED declares $0.20 dividend - August 29 at 4:16 PM logoCONMED Corporation (CNMD) Receives Hold Rating from KeyCorp - August 27 at 1:08 PM logoCONMED Corporation to Present at the Morgan Stanley Global Healthcare Conference - August 24 at 5:34 PM logoCONMED Corporation to Present at the Morgan Stanley Global Healthcare Conference - August 24 at 5:34 PM logoInsider Selling: CONMED Corporation (CNMD) Director Sells 3,000 Shares of Stock - August 15 at 8:00 PM logoETFs with exposure to CONMED Corp. : August 15, 2017 - August 15 at 6:03 PM logoSee what the IHS Markit Score report has to say about Conmed Corp. - August 12 at 4:52 PM logo$187.21 Million in Sales Expected for CONMED Corporation (NASDAQ:CNMD) This Quarter - August 11 at 9:28 AM logo Analysts Expect CONMED Corporation (CNMD) to Post $0.41 Earnings Per Share - August 9 at 10:50 PM logoReviewing CONMED Corporation (CNMD) and Asante Solutions (PUMP) - August 7 at 6:28 PM logoCONMED Corporation (NASDAQ:CNMD) Given Consensus Recommendation of "Hold" by Analysts - August 5 at 9:08 AM logoTheStreet Upgrades CONMED Corporation (NASDAQ:CNMD) to "B-" - August 5 at 8:58 AM logoCONMED Corp. breached its 50 day moving average in a Bearish Manner : CNMD-US : August 3, 2017 - August 3 at 5:13 PM logoCONMED Corp. :CNMD-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017 - August 1 at 6:04 PM logoKeyCorp Equities Analysts Lower Earnings Estimates for CONMED Corporation (NASDAQ:CNMD) - July 31 at 7:50 AM logoLeerink Swann Weighs in on CONMED Corporation's Q3 2017 Earnings (CNMD) - July 31 at 7:50 AM logoCONMED Corporation (NASDAQ:CNMD) Short Interest Update - July 29 at 7:15 AM logoBrokers Issue Forecasts for CONMED Corporation's Q1 2018 Earnings (NASDAQ:CNMD) - July 28 at 5:27 PM logoResearch Analysts Offer Predictions for CONMED Corporation's FY2017 Earnings (NASDAQ:CNMD) - July 28 at 9:31 AM logoCONMED (CNMD) Q2 2017 Results - Earnings Call Transcript - July 27 at 5:37 PM logoEdited Transcript of CNMD earnings conference call or presentation 26-Jul-17 8:30pm GMT - July 27 at 5:37 PM logoCONMED (CNMD) Earnings Meet, Revenues Beat Estimates in Q2 - July 27 at 5:37 PM logoCONMED Corporation (CNMD) Posts Quarterly Earnings Results, Meets Expectations - July 26 at 9:15 PM logoCONMED Corporation (NASDAQ:CNMD) Updates FY17 Earnings Guidance - July 26 at 7:42 PM logoInvestor Network: CONMED Corporation to Host Earnings Call - July 26 at 5:54 PM logoCONMED Corporation Announces Second Quarter 2017 Financial Results - July 26 at 5:54 PM logoConmed meets 2Q profit forecasts - July 26 at 5:54 PM logoETFs with exposure to CONMED Corp. : July 24, 2017 - July 24 at 4:56 PM logoCONMED Corporation (CNMD) Expected to Post Quarterly Sales of $194.70 Million - July 22 at 8:54 AM logoCONMED Corp. breached its 50 day moving average in a Bearish Manner : CNMD-US : July 21, 2017 - July 21 at 6:55 PM logo$0.42 Earnings Per Share Expected for CONMED Corporation (CNMD) This Quarter - July 20 at 6:27 PM logoETFs with exposure to CONMED Corp. : July 14, 2017 - July 14 at 7:21 PM



CONMED Corporation (CNMD) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.